ArticleBMC genomics2026
DcSE: an improved densenet with enhanced attention fusion for super-enhancer prediction.
Article in BMC genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundSuper-enhancers are critical cis-regulatory elements that play a central role in modulating gene expression and driving cellular identity. Their dysregulation is closely associated with the development of numerous major human diseases, particularly cancer. In this study, we propose DcSE, a novel deep learning framework designed for efficient and precise super-enhancer prediction. The core architecture is based on an enhanced DenseNet featuring an improved Convolutional Block Attention Module. Unlike standard serial processing, our module employs a dynamic fusion mechanism that adjusts the contributions of channel and spatial attention through learnable parameters. To further enhance robustness, DcSE adopts an ensemble learning framework utilizing cross-validation and multiple initializations.
resultsDcSE demonstrates exceptional performance on benchmark datasets for both human and mouse, surpassing existing state-of-the-art models across all evaluation metrics. It achieves 80.81% ACC and 87.86% AUC on the human dataset, along with 80.16% ACC and 87.04% AUC on the mouse dataset. Visual analysis through t-SNE confirms that the model learns highly separable, high-order feature representations from raw sequences. Furthermore, cross-species validation experiments prove the robust generalization capability of the framework. Motif analysis utilizing mask-based attribution methods successfully identifies species-specific key transcription factors, such as ZKSCAN3 in humans and STAT1 in mouse, providing clear biological interpretability.
conclusionsDcSE is a high-performance, robust, and interpretable computational tool. By accurately capturing key sequence features and providing biological insights into transcription factor regulation, it offers a reliable framework for super-enhancer identification and the study of genomic regulatory mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.